FIGHT against FGF/FGFR alterations: what are the next steps?
- PMID: 35450697
- DOI: 10.1016/j.annonc.2022.03.014
FIGHT against FGF/FGFR alterations: what are the next steps?
Conflict of interest statement
Disclosure YL: consulting or advisory Role: Janssen, Janssen (Inst), Astellas, Roche, AstraZeneca, Merck & Co., Kenilworth, NJ, Seattle Genetics, Bristol Myers Squibb, Immunomedics, and Taiho Pharmaceutical; travel, accommodation, expenses: Astellas, Janssen, Roche, Merck & Co., Kenilworth, NJ, AstraZeneca, and Seattle Genetics; honoraria: Sanofi and Pfizer; research funding: Sanofi (Inst), Janssen Oncology (Inst), Merck & Co., Kenilworth, NJ (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), Celsius (Inst), Exelixis (Inst), Incyte (Inst), Pfizer (Inst), and Nektar (Inst). All other authors have declared no conflicts of interest.
Comment on
-
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14. Ann Oncol. 2022. PMID: 35176457 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources